Free Trial

Thomas Deal Analyst Performance

Analyst at Raymond James Financial

Thomas Deal is a stock analyst at Raymond James Financial in the healthcare sector, covering 4 publicly traded companies. Over the past year, Thomas Deal has issued 4 stock ratings, including buy and hold recommendations. While full access to Thomas Deal's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Thomas Deal's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
4 Last 0 Years
Buy Recommendations
75.00% 3 Buy Ratings
Companies Covered
4 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy75.0%3 ratings
Hold25.0%1 ratings
Sell0.0%0 ratings

Out of 4 total stock ratings issued by Thomas Deal at Raymond James Financial, the majority (75.0%) have been Buy recommendations, followed by 25.0% Hold.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
4 companies

Thomas Deal, an analyst at Raymond James Financial, currently covers 4 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Healthcare
4 companies
100.0%

Thomas Deal of Raymond James Financial specializes in stock coverage within the Healthcare sector.

Coverage Industries

IndustryPercentage
BIOTECHNOLOGY
3 companies
75.0%
PHARMACEUTICALS
1 company
25.0%

Thomas Deal's Ratings History at Raymond James Financial

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
0 Results
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
10/9/2026Initiated Coverage$40.80Market Perform
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
10/8/2026Initiated Coverage$109.30$140.00Outperform
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
10/8/2026Initiated Coverage$1.45$6.00Outperform
ODTX
Odyssey Therapeutics
10/8/2026Initiated Coverage$18.12$42.00Outperform